Strategies that seek to enhance musculoskeletal tissue regeneration and repair by modulating the biologic microenvironment at the site of injury have considerable therapeutic potential. Current and emerging biologic approaches include the use of growth factors, platelet-rich plasma, stem cell therapy, and scaffolds. The American Academy of Orthopaedic Surgeons hosted a research symposium in November 2015 to review the current state-of-the-art biologic treatments of articular cartilage, muscle, tendon, and bone injuries and identify knowledge gaps related to these emerging treatments. This review outlines the findings of the symposium and summarizes the consensus reached on how best to advance research on biologic treatment of orthopaedic injuries.
From the Steadman Philippon Research Institute, Vail, CO (Dr. LaPrade), Stanford University, Redwood City, CA (Dr. Dragoo and Dr. Chu), NorthShore University HealthSystem, Chicago, IL (Dr. Koh), the University of Edinburgh, Edinburgh, United Kingdom (Dr. Murray), and Western Michigan University Homer Stryker M.D. School of Medicine, Kalamazoo, MI (Dr. Geeslin).
Dr. LaPrade or an immediate family member has received royalties from Arthrex and Smith & Nephew; serves as a paid consultant to Arthrex, Össur, and Smith & Nephew; has received research or institutional support from Arthrex, ConMed Linvatec, Össur, and Smith & Nephew; and serves as a board member, owner, officer, or committee member of the American Orthopaedic Society for Sports Medicine, the Arthroscopy Association of North America, the European Society for Sports Traumatology, Knee Surgery and Arthroscopy, and the International Society of Arthroscopy, Knee Surgery and Orthopaedic Sports Medicine. Dr. Dragoo or an immediate family member serves as a paid consultant to or is an employee of Becton Dickinson, ConMed Linvatec, DePuy Synthes, Genzyme, Moximed, Össur, and RNL Bio; has received research or institutional support from ConMed Linvatec and Össur; has received nonincome support (such as equipment or services), commercially derived honoraria, or other non-research–related funding (such as paid travel) from EmCyte; and serves as a board member, owner, officer, or committee member of the American Orthopaedic Society for Sports Medicine. Dr. Koh or an immediate family member serves as a paid consultant to or is an employee of Aesculap/B. Braun Medical, Aperion Biologics, and Arthrex; has stock or stock options held in Aperion Biologics; and serves as a board member, owner, officer, or committee member of the American Orthopaedic Society for Sports Medicine, the Arthroscopy Association of North America, the Illinois Association of Orthopaedic Surgeons, and the Patellofemoral Foundation. Dr. Chu or an immediate family member serves as a board member, owner, officer, or committee member of the American Orthopaedic Society for Sports Medicine. Neither of the following authors nor any immediate family member has received anything of value from or has stock or stock options held in a commercial company or institution related directly or indirectly to the subject of this article: Dr. Murray and Dr. Geeslin.
Received February 03, 2016
